David Spigel, MD, discusses the findings from and methodology behind the ADRIATIC study of durvalumab as consolidation therapy for patients with limited-stage small cell lung cancer.

The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a ...

Gwen Nichols, MD, discussed the potential implications of recent funding cuts, how they are affecting academic and community ...

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

A study found a 94% 6-month survival rate after tandem autologous stem cell transplant for high-risk neuroblastoma, but ...

Panelists discuss how treatment sequencing decisions in myelofibrosis should be guided by clinical evidence, patient response ...

Panelists discuss how the timing of therapeutic interventions in early-stage myelofibrosis must be carefully weighed against ...

Andrew Kuykendall, MD, discusses the background, methods, and design of a phase 2 study which evaluated fedratinib.

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible ...

Hany Elmariah, MD, discussed the safety profile of fedratinib and its evolving role in the post-transplant setting for patients with myeloproliferative neoplasms.